New drugs for medullary thyroid cancer: new promises?
نویسندگان
چکیده
منابع مشابه
New drugs for medullary thyroid cancer: new promises?
Medullary thyroid cancer (MTC) is a rare tumor arising from the calcitonin-producing parafollicular C cells of the thyroid gland, occurring either sporadically or alternatively in a hereditary form based on germline RET mutations in approximately one-third of cases. Historically, patients with advanced, metastasized MTC have had a poor prognosis, partly due to limited response to conventional c...
متن کاملNEW DRUGS Cometriq for Thyroid Cancer
NEW DRUGS Cometriq for Thyroid Cancer Cabozantinib (Cometriq, Exelixis) has been approved with an orphan drug designation to treat metastatic medullary thyroid cancer (MTC). Cabozantinib blocks abnormal kinase proteins involved in the development and growth of medullary cancer cells. In a clinical study, treatment with cabozantinib increased progression-free survival and, in some patients, redu...
متن کاملMedullary Thyroid Cancer: A Review
Thyroid cancer is a malignancy of the thyroid parenchymal cells. There are four main types of thyroid cancer: papillary thyroid cancer (PTC), follicular thyroid cancer (FTC), anaplastic thyroid carcinoma (ATC), and Medullary thyroid carcinoma (MTC). Medullary thyroid cancer (MTC) is a rare neuroendocrine tumor of the thyroid gland derived from parafollicular C-cells that produce calcitonin (CT...
متن کاملGenetic and Epigenetic of Medullary Thyroid Cancer
Medullary thyroid carcinoma (MTC) is an infrequent calcitonin-producing neuroendocrine tumor that initiates from the parafollicular C cells of the thyroid gland. Several genetic and epigenetic alterations are collaterally responsible for medullary thyroid carcinogenesis. In this review article, we shed light on all the genetic and epigenetic hallmarks of MTC. From the genetic perspective, RET, ...
متن کاملNew drugs for breast cancer.
Recently there have been significant advances in rational drug design for the treatment of breast cancer, especially in the area of targeted drug therapy. These include drugs which target the HER2 receptor and angiogenesis and the novel class of drug the PARP inhibitors. Some of these agents, for example, trastuzumab used in the treatment of HER2 positive breast cancer are already established a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Endocrine-Related Cancer
سال: 2016
ISSN: 1351-0088,1479-6821
DOI: 10.1530/erc-16-0104